Patrick Zweidler-McKay
Company: Sidewinder Therapeutics
Job title: Fractional Chief Medical Officer
Bio:
Patrick serves as Chief Medical Officer of Sidewinder Therapeutics. Prior to Sidewinder, he was Executive Director at ImmunoGen and Global Development Lead at AbbVie. He has focused exclusively on ADC programs, leading 12 ADC development candidates, including five clinical stage programs, one of which is approved (Elahere) and a second to be reviewed by FDA in 2025. At ImmunoGen, he worked closely with the C-suite, leading BD interactions for both outgoing and incoming programs. Prior to ImmunoGen, Patrick served as Deputy Department Chair of Pediatric Oncology at MD Anderson Center, where he led the Leukemia & Lymphoma Section, and ran a two R01-funded research laboratory. In addition, Patrick chaired international clinical trials, served as a full member of the Clinical Oncology Study Section, Pediatric Editor for CANCER, and an expert reviewer for the National Academy of Sciences, among other achievements. He has published over 76 research papers and book chapters in oncology and has >10,000 citations.
Seminars:
Session Chair’s Opening Remarks 7:50 am
day: Day One P1
Investor Icebreaker: When Being Selective, where will Investors Invest? 11:45 am
For both venture and investing out of public funds, what will drive investment in ADCs and what will inhibit it? With the data readouts from ASCO, will your considerations for investment change? How can and will ADCs remain relevant to investors?Read more
day: Day One P2
The Calm Before the Storm: Navigating a Tidal Wave of ADCs 9:00 am
day: Day One Red Track